HSBC/CALL/AMGEN/260/0.1/15.01.25 | Real-time BOERSE MUENCHEN 11:35:40 2024-07-02 EDT | ||
| 5.69 EUR | -1.39% |
|
| Current month | -1.54% | ||
| 1 month | +5.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 5.69 | -1.39% |
| 24-07-01 | 5.77 | -1.54% |
| 24-06-28 | 5.86 | -0.85% |
| 24-06-27 | 5.91 | -1.34% |
| 24-06-26 | 5.99 | -7.85% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 11:35 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | HSBC |
| WKN | HG8K73 |
| ISIN | DE000HG8K735 |
| Date issued | 2023-02-28 |
| Strike | 260 $ |
| Maturity | 2025-01-15 (197 Days) |
| Parity | 10 : 1 |
| Emission price | 2.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.39 € |
|---|---|
| Lowest since issue | 1.06 € |
| Spread | 0.03 € |
| Spread % | 0.53% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311
USD
Average target price
316.4
USD
Spread / Average Target
+1.75%
- Stock Market
- Warrants
- Warrant
